Efficacy of olanzapine: an overview of pivotal clinical trials.
Efficacy of olanzapine: an overview of pivotal clinical trials.
复制标题
DOI：
--
复制
发表时间：
1997-02
期刊：
影响因子：
--
通讯作者：
C. Beasley;G. Tollefson;P. Tran
中科院分区：
文献类型：
--
作者：
C. Beasley;G. Tollefson;P. Tran
奥氮平是一种新的“非典型”抗精神病药物，化学上属于噻吩并苯二氮类。与D2受体相比，其对5-HT 2的相对更大的结合亲和力使其类似于非典型药物氯氮平，一种5-羟色胺/多巴胺拮抗剂。列出了4项比较奥氮平与安慰剂和/或氟哌啶醇的双盲关键性研究。结果表明，奥氮平对精神分裂症的阳性症状与氟哌啶醇一样有效，对精神分裂症的阴性症状比氟哌啶醇更有效。
Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similar to the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies, which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest that olanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidol for the treatment of the negative symptoms of schizophrenia.